A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases

OBJECTIVE: No efficient medical treatment is available for severe acute hepatitis (SAH) except N-acetylcysteine for acetaminophen-induced acute liver failure. The human C-type lectin Reg3α, referred to as ALF-5755, improved survival in an animal model of acute liver failure and was well tolerated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nalpas, Bertrand, Ichaï, Philippe, Jamot, Laure, Carbonell, Nicolas, Rudler, Marika, Mathurin, Philippe, Durand, François, Gerken, Guido, Manns, Michael, Trautwein, Christian, Larrey, Dominique, Radenne, Sylvie, Duvoux, Christophe, Leroy, Vincent, Bernuau, Jacques, Faivre, Jamila, Moniaux, Nicolas, Bréchot, Christian, Amouyal, Gilles, Amouyal, Paul, Samuel, Didier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794150/
https://www.ncbi.nlm.nih.gov/pubmed/26983031
http://dx.doi.org/10.1371/journal.pone.0150733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794150/
https://www.ncbi.nlm.nih.gov/pubmed/26983031
http://dx.doi.org/10.1371/journal.pone.0150733

Ejemplares similares